NEW YORK, July 22 (Reuters) – Rising Pharma Holdings Inc. has recalled millions of bottles of cetirizine hydrochloride tablets, a common antihistamine, over potentially life-threatening cross-contamination with another active drug. The recall affects over-the-counter allergy medication sold nationwide.
The U.S. Food and Drug Administration posted the recall notice on July 18. The company initiated it after discovering that certain lots might contain trace amounts of a different pharmaceutical ingredient. The contaminant has not been publicly identified. The risk: severe allergic reactions, cardiac issues, or anaphylaxis in sensitive patients.
This is not a minor production error. Cross-contamination occurs when shared manufacturing equipment is inadequately cleaned between runs. For allergy sufferers, many of whom have compromised respiratory systems, the introduction of an unintended drug—such as a beta-blocker or sedative—can trigger a cascade of adverse effects. Vulnerable populations—children, the elderly, those with asthma or pre-existing heart conditions—face amplified danger.
Which products are affected? The recall covers specific bottles of cetirizine hydrochloride tablets, 10 mg, sold under the Rising Pharma label. Consumers must check three data points on the bottle label: the National Drug Code (NDC), the lot number, and the expiration date. The FDA has published the full list on its enforcement database.
Affected NDCs include 16571-0521-01 (bottle of 100 tablets) and 16571-0521-02 (bottle of 1000 tablets). Lot numbers range from 2401B01 to 2404B20. Expiration dates fall between March 2026 and September 2026. Do not take tablets matching these identifiers. Return them to the point of purchase for a full refund or replacement.
If you have consumed a recalled product without immediate symptoms, monitor yourself. Seek medical attention for difficulty breathing, swelling, rapid heartbeat, or dizziness. Contact Rising Pharma’s recall hotline at 1-855-225-0927.
Industry experts point to a troubling trend. “Manufacturing errors are rising as supply chains become more complex,” said Dr. Ellen Huang, a pharmacovigilance consultant at HA Viewpoint, a pharmaceutical safety analytics firm. HA Viewpoint’s internal data shows a 23% increase in cross-contamination related recalls since 2023 across antihistamine products. The FDA has stepped up inspections, but enforcement actions lag behind production volume.
The recall erodes consumer trust in over-the-counter drugs. Allergy medication is a $4 billion annual market in the United States. Millions rely on cetirizine as a first-line treatment.
Protect yourself. Sign up for FDA recall alerts. Always verify batch numbers before use. When in doubt, consult a pharmacist. Report any adverse events directly to the FDA’s MedWatch program.
Share this information. It could prevent a hospital visit.
💡 Frequently Asked Questions (FAQ)
- Q: Which allergy medication is being recalled?
- A: Rising Pharma Holdings Inc. is recalling millions of bottles of cetirizine hydrochloride tablets (10 mg), a common over-the-counter antihistamine, due to potential cross-contamination with another active drug.
- Q: Why was the allergy medication recalled?
- A: The recall was initiated after discovering that certain lots might contain trace amounts of an unidentified pharmaceutical ingredient, posing risks of severe allergic reactions, cardiac issues, or anaphylaxis in sensitive patients.
- Q: How can I tell if my allergy medication is affected?
- A: Check the bottle label for three data points: the National Drug Code (NDC), the lot number, and the expiration date. The FDA has published the full list of affected lots on its enforcement database.
- Q: What is cross-contamination in medication manufacturing?
- A: Cross-contamination occurs when shared manufacturing equipment is inadequately cleaned between production runs, leading to unintended drug residues that can cause adverse reactions in patients.
- Q: Who is most at risk from this recall?
- A: Vulnerable populations such as children, the elderly, and individuals with asthma, pre-existing heart conditions, or compromised respiratory systems face amplified danger of life-threatening reactions.
Extended Reading
For the official recall notice and complete list of lot numbers, visit the FDA’s recall database at www.fda.gov/safety/recalls. HA Viewpoint’s 2024 Pharmacovigilance Report provides further analysis on manufacturing contamination trends in over-the-counter medications.